Citius Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
12/08/2025 21:53
Citius Pharmaceuticals Inc CTXR.OQ reported a quarterly adjusted loss of 80 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.50. The mean expectation of three analysts for the quarter was for a loss of 59 cents per share. Wall Street expected results to range from -80 cents to -21 cents per share. Reported revenue was zero; analysts expected $4.32 million. Citius Pharmaceuticals Inc's reported EPS for the quarter was a loss of 80 cents. The company reported a quarterly loss of $8.79 million. Citius Pharmaceuticals Inc shares had fallen by 21.4% this quarter and lost 68.7% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 10.2% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $5.00, about 75% above its last closing price of $1.25 This summary was machine generated from LSEG data August 12 at 08:53 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.59 | -0.80 | Missed |
| Mar. 31 2025 | -0.38 | -1.27 | Missed |
| Dec. 31 2024 | -0.58 | -1.30 | Missed |
| Sep. 30 2024 | -1.50 | -1.59 | Missed |
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules